文献速递新药、器械与细胞基因治疗研发基础与转化研究

癌症免疫治疗的心血管毒性

Cardiovascular toxicity of immune therapies for cancer.
PubMed 文献 · BMJ · 2024-05-15

本文综述免疫检查点抑制剂(ICI)与嵌合抗原受体T细胞疗法(CAR-T)相关心血管不良反应的现有认识。ICI可伴发心肌炎(少见但高度致死)、心包炎与心包积液、血管炎、血栓栓塞及可能加速的动脉粥样硬化;CAR-T所致全身细胞因子释放综合征可伴多种心血管后果,包括心律失常、心肌梗死和心力衰竭。

要点

  • ICI可伴发心肌炎,虽少见但高度致死。
  • ICI还与心包炎与心包积液、血管炎、血栓栓塞及可能加速的动脉粥样硬化相关。
  • CAR-T所致全身细胞因子释放综合征可伴心律失常、心肌梗死和心力衰竭。

核心结论

  • 本文综述了ICI与CAR-T相关心血管不良反应的现有知识状态。

研究设计与样本

  • 本文为综述,总结ICI与CAR-T相关心血管不良反应的现有认识。

主要发现

  • ICI的使用与心肌炎相关,为较少见但高度致死的不良反应。
  • ICI的使用还与心包炎与心包积液、血管炎、血栓栓塞以及可能加速的动脉粥样硬化相关。
  • CAR-T引起全身细胞因子释放综合征,与多种心血管后果相关,包括心律失常、心肌梗死和心力衰竭。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In addition to conventional chemoradiation and targeted cancer therapy, the use of immune based therapies, specifically immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T cell therapy (CAR-T), has increased exponentially across a wide spectrum of cancers. This has been paralleled by recognition of off-target immune related adverse events that can affect almost any organ system including the cardiovascular system. The use of ICIs has been associated with myocarditis, a less common but highly fatal adverse effect, pericarditis and pericardial effusions, vasculitis, thromboembolism, and potentially accelerated atherosclerosis. CAR-T resulting in a systemic cytokine release syndrome has been associated with myriad cardiovascular consequences including arrhythmias, myocardial infarction, and heart failure. This review summarizes the current state of knowledge regarding adverse cardiovascular effects associated with ICIs and CAR-T.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Palaskas NL, Ali HJ, Koutroumpakis E, et al. Cardiovascular toxicity of immune therapies for cancer. BMJ. 2024. PMID: 38749554. doi:10.1136/bmj-2023-075859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。